Discriminative Ability of Left Ventricular Strain in Mildly Reduced Ejection Fraction Heart Failure
Journal
JACC: Advances
Journal Volume
2
Journal Issue
9
Pages
100654
Date Issued
2023-11-01
Author(s)
Chung, Fa Po
Chao, Tze Fan
Lee, An Sheng
Sung, Kuo Tzu
Huang, Wen Hung
Hsiao, Chih Chung
Su, Cheng Huang
Chen, Ying Ju
Chen, Yun Yu
Liao, Jo Nan
Jia-Yin Hou, Charles
Yeh, Hung I.
Hung, Chung Lieh
Abstract
Background: Left ventricular (LV) systolic strain is presumably a more sensitive myocardial indicator than LV ejection fraction (LVEF). Data regarding the use of LV strain in clinical risk stratification and in identifying angiotensin receptor-neprilysin inhibitor (ARNi) responders remain scarce in heart failure with mildly reduced ejection fraction (HFmrEF). Objectives: The authors aimed to examine whether assessing LV strain may provide prognostic insight beyond LVEF and help discriminate the therapeutic efficacy of ARNi in HFmrEF patients. Methods: LVEF and LV strain were quantified among 1,075 first-time hospitalized HFmrEF patients (mean age: 68.1 ± 15.1 years, 40% female). The MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) risk score and its components were calculated. A Cox proportional hazard model was constructed for time-to-event analysis. Restrictive cubic spline curves were used to model the therapeutic effects of ARNi against renin-angiotensin system inhibitor according to baseline LVEF or LV strain. Results: LV strain showed a statistically significant inverse association with MAGGIC cardiac risk (coefficient: −0.14, P < 0.001). LV strain was independently associated with clinical outcomes after accounting for LVEF. MAGGIC-LV strain strata outperformed MAGGIC-LVEF strata in overall survival (Harrell's C-index: 0.71 and 0.56, P for difference <0.001; category-free net reclassification index: 0.44, P < 0.001). Lower LV strain but not LVEF consistently showed the beneficial therapeutic effects of ARNi against renin-angiotensin system inhibitor by Cox models and restrictive cubic spline (all Pinteraction <0.05). Conclusions: Among HFmrEF patients, LV strain may serve as an attractive systolic marker and provide a better prognostic and therapeutic discriminative measure for ARNi treatment than conventional LVEF.
Subjects
angiotensin receptor neprilysin inhibitor (ARNi) | heart failure with mildly reduced ejection fraction | LV ejection fraction | LV strain | MAGGIC score | renin-angiotensin system inhibitors (RASi)
Type
journal article